The estimated Net Worth of Curt H La Belle is at least $15.7 mil dollars as of 11 July 2019. Curt Belle owns over 17,985 units of Eyenovia Inc stock worth over $15,672 and over the last 7 years he sold EYEN stock worth over $0. In addition, he makes $0 as Director at Eyenovia Inc.
Sign up
Curt Labelle EYEN stock SEC Form 4 insiders trading
Curt has made over 3 trades of the Eyenovia Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 17,985 units of EYEN stock worth $49,998 on 11 July 2019.
The largest trade he's ever made was exercising 140,000 units of Eyenovia Inc stock on 2 January 2019 worth over $173,600. On average, Curt trades about 23,998 units every 75 days since 2018. As of 11 July 2019 he still owns at least 27,985 units of Eyenovia Inc stock.
You can see the complete history of Curt Belle stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Curt Labelle biography
Dr. Curt H. Labelle M.D. serves as Director of the Company. Since July 2015, he has been the managing partner at the Global Health Investment Advisors, LLC and, prior to that, was a managing director at Tullis Health Investors Inc. from 2008 to 2015. From April 2011 to May 2015, Dr. LaBelle served as a member of the board of directors of Exagen Diagnostics, Inc. (now known as Exagen, Inc. (NASDAQ: XGN), a commercial stage autoimmune rheumatic disease diagnostics company, and was chairman from December 2011 to May 2015. Dr. LaBelle served as chairman of the board of SafeOp Surgical, Inc., a medical device and technology company acquired by Alphatec Holdings, Inc. (NASDAQ: ATEC), from 2011 to 2015, and Impulse Monitoring, Inc., a neuromonitoring company, from 2008 to 2011 when the company was acquired by NuVasive, Inc. (NASDAQ: NUVA). From 2006 to 2008, Dr. LaBelle served as a member of the board of directors of Sirion Therapeutics, Inc., a company that developed Durezol for ophthalmic post-operative inflammation (acquired by Alcon Inc. (NYSE: ALC)), Zirgan for ocular herpetic keratitis (acquired by Bausch & Lomb Holdings, Inc.), as well as a development program for a topical vancomycin for serious eye infections (acquired by Perrigo Company plc (NYSE: PRGO)). He was also a member of the board of directors of KAI Pharmaceuticals, Inc., apharmaceutical company developing drugs for patients with chronic kidney disease, since May 2006 until the company was acquired by Amgen Inc. (NASDAQ: AMGN) in July 2012, and TransMolecular, Inc., a neuroscience biotechnology company developing products to treat central nervous system disorders (acquired by Morphotek, Inc.).
How old is Curt Labelle?
Curt Labelle is 49, he's been the Director of Eyenovia Inc since 2014. There are 9 older and 3 younger executives at Eyenovia Inc. The oldest executive at Eyenovia Inc is Ernest Mario, 81, who is the Independent Director.
What's Curt Labelle's mailing address?
Curt's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Insiders trading at Eyenovia Inc
Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant y Fredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.
What does Eyenovia Inc do?
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
What does Eyenovia Inc's logo look like?
Complete history of Curt Belle stock trades at Eyenovia Inc
Eyenovia Inc executives and stock owners
Eyenovia Inc executives and other stock owners filed with the SEC include:
-
Tsontcho Ianchulev,
Chief Executive Officer, Director, Chief Medical Officer -
Dr. Tsontcho Ianchulev M.P.H., M.D., MPH,
CEO, Pres, Chief Medical Officer & Director -
John Gandolfo,
Chief Financial Officer, Secretary -
John P. Gandolfo CPA,
CFO & Sec. -
Michael Rowe,
Vice President - Commercial -
Jennifer Clasby,
Vice President - Clinical Operations -
Michael M. Rowe,
Chief Operating Officer -
Fredric Eshelman,
Independent Chairman of the Board -
Tram Bui,
IR Contact Officer -
Anthony Sun,
Independent Director -
Charles Mather,
Independent Director -
Ernest Mario,
Independent Director -
Kenneth Lee,
Independent Director -
Curt Labelle,
Director -
Luke Clauson,
Vice President - Research &Development and Manufacturing -
Norbert Lowe,
VP of Sales & Marketing -
Alexander Lobo,
Investor Contact -
Andrew D. Jones,
Chief Financial Officer -
Julia A Haller,
-
Bren Kern,
Chief Operating Officer -
Pharmaceutical Co., Ltd. Senju,
10% owner -
Shuhei Yoshida,
Director -
Stuart M. Grant,
-
Stephen Keith Benjamin,
-
Rachel Jacobson,
Director -
Ellen R Strahlman,
Director -
Michael S Geltzeiler,
Director -
Ram Palanki,
Director